Bristol-Myers Squibb Company (BMY) - Total Assets
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) holds total assets worth $86.48 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Bristol-Myers Squibb Company (BMY) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Bristol-Myers Squibb Company - Total Assets Trend (1987–2025)
This chart illustrates how Bristol-Myers Squibb Company's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Bristol-Myers Squibb Company to see how much of total assets are deployed in long-term investments.
Bristol-Myers Squibb Company - Asset Composition Analysis
Current Asset Composition (December 2025)
Bristol-Myers Squibb Company's total assets of $86.48 Billion consist of 32.6% current assets and 67.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $10.21 Billion | 11.3% |
| Accounts Receivable | $14.53 Billion | 16.1% |
| Inventory | $2.69 Billion | 3.0% |
| Property, Plant & Equipment | $9.12 Billion | 10.1% |
| Intangible Assets | $19.10 Billion | 21.2% |
| Goodwill | $21.75 Billion | 24.2% |
Asset Composition Trend (1987–2025)
This chart illustrates how Bristol-Myers Squibb Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BMY stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bristol-Myers Squibb Company's current assets represent 32.6% of total assets in 2025, a decrease from 66.6% in 1987.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 31.2% in 1987.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 4.0% in 1987.
- Asset Diversification: The largest asset category is goodwill at 24.2% of total assets.
Bristol-Myers Squibb Company Competitors by Total Assets
Key competitors of Bristol-Myers Squibb Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $207.62 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.29 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Bristol-Myers Squibb Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.28 | 1.54 |
| Quick Ratio | 1.28 | 1.17 | 1.42 |
| Cash Ratio | 0.00 | 0.45 | 0.58 |
| Working Capital | $8.05 Billion | $6.71 Billion | $10.17 Billion |
Bristol-Myers Squibb Company - Advanced Valuation Insights
This section examines the relationship between Bristol-Myers Squibb Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.80 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | -2.8% |
| Total Assets | $90.04 Billion |
| Market Capitalization | $112.89 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Bristol-Myers Squibb Company's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Bristol-Myers Squibb Company's assets decreased by 2.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bristol-Myers Squibb Company (1987–2025)
The table below shows the annual total assets of Bristol-Myers Squibb Company from 1987 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $90.04 Billion | -2.77% |
| 2024-12-31 | $92.60 Billion | -2.69% |
| 2023-12-31 | $95.16 Billion | -1.72% |
| 2022-12-31 | $96.82 Billion | -11.43% |
| 2021-12-31 | $109.31 Billion | -7.74% |
| 2020-12-31 | $118.48 Billion | -8.82% |
| 2019-12-31 | $129.94 Billion | +271.42% |
| 2018-12-31 | $34.99 Billion | +4.28% |
| 2017-12-31 | $33.55 Billion | -0.46% |
| 2016-12-31 | $33.71 Billion | +6.17% |
| 2015-12-31 | $31.75 Billion | -5.93% |
| 2014-12-31 | $33.75 Billion | -12.55% |
| 2013-12-31 | $38.59 Billion | +7.51% |
| 2012-12-31 | $35.90 Billion | +8.88% |
| 2011-12-31 | $32.97 Billion | +6.09% |
| 2010-12-31 | $31.08 Billion | +0.22% |
| 2009-12-31 | $31.01 Billion | +5.16% |
| 2008-12-31 | $29.49 Billion | +12.66% |
| 2007-12-31 | $26.17 Billion | +2.33% |
| 2006-12-31 | $25.57 Billion | -9.11% |
| 2005-12-31 | $28.14 Billion | -7.55% |
| 2004-12-31 | $30.43 Billion | +10.88% |
| 2003-12-31 | $27.45 Billion | +9.70% |
| 2002-12-31 | $25.02 Billion | -7.52% |
| 2001-12-31 | $27.06 Billion | +53.93% |
| 2000-12-31 | $17.58 Billion | +2.71% |
| 1999-12-31 | $17.11 Billion | +5.17% |
| 1998-12-31 | $16.27 Billion | +8.65% |
| 1997-12-31 | $14.98 Billion | +1.99% |
| 1996-12-31 | $14.69 Billion | +5.43% |
| 1995-12-31 | $13.93 Billion | +7.89% |
| 1994-12-31 | $12.91 Billion | +6.69% |
| 1993-12-31 | $12.10 Billion | +12.00% |
| 1992-12-31 | $10.80 Billion | +14.74% |
| 1991-12-31 | $9.42 Billion | +2.18% |
| 1990-12-31 | $9.21 Billion | +8.45% |
| 1989-12-31 | $8.50 Billion | +2.71% |
| 1988-12-31 | $8.27 Billion | +10.10% |
| 1987-12-31 | $7.51 Billion | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for… Read more